Diagnostyka reports 23% revenue growth in Q1 2025
Diagnostyka, the leader in the medical diagnostics market in Poland, continues to consistently implement its development strategy based on organic growth and acquisitions. In Q1 2025, revenue from contracts with customers reached PLN 591.5 million, marking a year-on-year increase of over 23%. Recurring EBITDA1) increased by 18% y/y to PLN 161.2 million, while the number of tests performed grew by more than 8% to 45.2 million. The strong financial performance was driven by record sales under the “40 PLUS Prevention” program and favorable market trends.
We are pleased with the results achieved in the first quarter of 2025. Our business continues to grow organically, supported by both rising test volumes and a steady increase in pricing. We still observe positive market dynamics, which benefit our operations, yet we also consistently pursue our development strategy, including active participation in the M&A market. This quarter, our financial results were significantly supported by the '40 PLUS Prevention' program due to heightened patient interest during the final months of the initiative.”
In Q1 2025, Diagnostyka recorded a 8.3% y/y increase in the number of tests performed, reaching 45.2 million. The average test price rose by 14.1% y/y, supported by an improved product mix – including higher pricing for genetic and histopathological tests – and the consolidation of imaging businesses.
During the past quarter, Diagnostyka completed two selective acquisitions: Central Laboratory of Medical Analytics – Laboratory Diagnostics Unit Anna Bądel, and Medical Laboratory NZOZ Tarnów led by Krystyna Gródecka, MSc. Both transactions are intended to strengthen the Company’s leading position in the laboratory diagnostics market and expand service accessibility in selected regions of Poland.
At the beginning of April, Eurodiagnostic – a provider of mobile diagnostic imaging units (CT, MRI, and X-ray) – joined the Diagnostyka Group.
We see significant growth potential in the diagnostic imaging segment and plan further selective acquisitions to broaden our offering and strengthen our market presence in this area
The “40 PLUS Prevention” program concluded in April 2025. As a continuation of preventive healthcare efforts, the Ministry of Health launched a new program in May – “My Health – Adult Health Check-up,” which is available to all individuals over 20 years of age.
The 'My Health' program has only just begun, so it is too early to evaluate its impact on our business. However, one thing is certain – the program’s focus on increasing public awareness of preventive healthcare is fully aligned with our mission. Diagnostyka will continue to leverage its experience and best practices to support public health initiatives and encourage Poles to take care of their health. At the same time, we will seek new opportunities to further unlock the potential of preventive diagnostics, including the continued development of our comprehensive diagnostics and Longevity segments.
In the last quarter, Diagnostyka generated PLN 132.3 million in operating cash flow, up from PLN 102.6 million a year earlier, confirming the Company’s strong ability to generate cash and finance further growth from internal resources.
We closed the first quarter of 2025 in line wikt our budget assumptions, which confirms the stability of our business model. The Recurring EBITDA margin exeeded 27% in this period, which is a satisfying result and provides a soil foundation for achieving our goals in the coming quarters.
Go back to homepage